|
Tepotinib in patients (pts) with NSCLC with MET exon 14 (METex14) skipping: Health-related quality of life (HRQoL). |
|
|
Honoraria - AstraZeneca; Boehringer Ingelheim; Calithera Biosciences; Celgene; EMD Serono; Takeda |
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Calithera Biosciences; Celgene; EMD Serono; Takeda |
Research Funding - Celgene; EMD Serono |
Travel, Accommodations, Expenses - EMD Serono |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; EMD Serono; Genentech; Incyte; Merck; Pfizer; Tesaro; Xcovery |
Research Funding - Boehringer Ingelheim (Inst); Xcovery (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Xcovery |
|
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Pfizer; Roche/Genentech |
|
|
Consulting or Advisory Role - Abbvie; AstraZeneca; Takeda Science Foundation |
|
|
Honoraria - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; MSD; Novartis; Pfizer; Roche/Genentech |
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; MSD; Novartis; Pfizer; Roche/Genentech; Takeda; Takeda; Takeda |
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Takeda (Inst) |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD; Roche; Takeda |
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD Oncology; Novartis; Pfizer; Takeda |
Research Funding - Ono Pharmaceutical; Pfizer; Roche; Takeda |
|
|
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Merck KGaA (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Novartis (Inst); Regeneron (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst) |
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst) |
|
|
|
Honoraria - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck KGaA; Merck Sharp & Dohme; Nippon Kayaku; Nitto Denko; Novartis; Ono Pharmaceutical; Pfizer; Roche; Shionogi; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda |
Consulting or Advisory Role - Abbvie; AstraZeneca; Chugai Pharma; Lilly; Merck Serono; MSD; Nitto Denko; Pfizer |
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb; Chugai Pharma (Inst); Kyorin; Kyowa Hakko Kirin; Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novartis; Ono Pharmaceutical (Inst); Pfizer (Inst); Regeneron; Taiho Pharmaceutical (Inst) |
|
|
Consulting or Advisory Role - AstraZeneca; EMD Serono; Lilly |
|
|
|
No Relationships to Disclose |
|
|
|
|
|
|
|
|
|
|
|
Stock and Other Ownership Interests - Bridgebio; Gencurix; Theravance |
Honoraria - AstraZeneca; Bayer; Champions Oncology; Dizal Pharma; Dong-A ST; Janssen; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan |
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda; Yuhan |
Speakers' Bureau - Novartis |
Research Funding - AstraZeneca; Bayer; Champions Oncology; Dizal Pharma; Dong-A ST; Janssen; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan |
Patents, Royalties, Other Intellectual Property - Champions Oncology |